1. SchiødtFV, AtillasoyE, ShakilAO, et al.Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg1999;5:29. CrossRef

2. OstapowiczG, FontanaRJ, LarsonAM, et al.; ALF Study Group. Etiology and outcome of acute liver failure in the USA: preliminary results of a prospective multi‐center study. Hepatology1999;30:221A.

3. LeeWM. Medical progress: drug‐induced hepatotoxicity. N Engl J Med2003;349:474. CrossRef

4. SgroC, CliniardF, OuazirK, et al.Incidence of drug‐induced hepatic injuries: a French population‐based study. Hepatology2002;36:451. CrossRef

5. BjornssonE, JerlstadP, BergquistA, et al.Fulminant drug‐induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol2005;40:1095. CrossRef

6. BjörnssonES, BergmannOM, BjörnssonHK, et al.Incidence, presentation, and outcomes in patients with drug‐induced liver injury in the general population of Iceland. Gastroenterology2013;144:1419. CrossRef

7. DevarbhaviH, SinghR, PatilM, et al.Outcome and determinants of mortality in 269 patients with combination anti‐tuberculosis drug‐induced liver injury. J Gastroenterol Hepatol2013;28:161. CrossRef

8. PortmannB, TalbotIC, DayDW, et al.Histopathological changes in the liver following a paracetamol overdose: correlation with clinical and biochemical parameters. J Pathol1975;117:169. CrossRef

9. AndreasenPB, HuttersL. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand1979;624(Suppl):99.

10. GaedigkA, BlumM, GaedigkR, et al.Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet1991;48:943.

11. KitaT, TanigawaraY, ChikazawaS, et al.N‐Acetyltransferase‐2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull2001;24:544. CrossRef

12. UetrechtJ, NaisbittDJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev2013;65:779. CrossRef

13. RobinMA, Le RoyM, DescatoireV, et al.Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug‐induced hepatitis. J Hepatol1997;26(Suppl 1):23. CrossRef

14. KennaJG. Immunoallergic drug‐induced hepatitis: lessons from halothane. J Hepatol1997;26(Suppl 1):5. CrossRef

15. JoshiPH, ConnHO. The syndrome of methoxyflurane‐associated hepatitis. Ann Intern Med1974;80:395. CrossRef

16. KlineMM. Enflurane‐associated hepatitis. Gastroenterology1980;79:126.

17. ScheiderDM, KlygisLM, TsangTK, et al.Hepatic dysfunction after repeated isoflurane administration. J Clin Gastroenterol1993;17:168. CrossRef

18. HautekeeteML, HorsmansY, Van WaeyenbergeC, et al.HLA association of amoxicillin‐clavulanate‐induced hepatitis. Gastroenterology1999;117:1181. CrossRef

19. Edwards‐SmithCJ, JonssonJR, PurdieDM, et al.Interleukin‐10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology1999;30:526. CrossRef

20. GroveJ, DalyAK, BassendineMF, et al.Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut2000;46:540. CrossRef

21. BernalW, DonaldsonP, UnderhillJ, et al.Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)‐induced acute liver failure. J Hepatol1998;29:53. CrossRef

22. DalyAJ, AithalGP, LeathartJBS, et al.Genetic susceptibility to diclofenac‐induced hepatotoxicity: contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. Gastroenterology2007;132:261. CrossRef

23. DalyAK, DonaldsonPT, BhatnagarP, et al.HLA‐B*5701 genotype is a major determinant of drug‐induced liver injury due to flucloxacillin. Nat Genet2009;41:816. CrossRef

24. JenkinsRE, YaseenFS, MonshiMM, et al.β‐Lactam antibiotics form distinct haptenic structures on albumin and activate drug‐specific T‐lymphocyte responses in multiallergic patients with cystic fibrosis. Chem Res Toxicol2013;26:963. CrossRef

25. MetushiIG, SandersC, LeeWM, et al.Detection of anti‐isoniazid and anti‐cyp antibodies in patients with isoniazid‐induced liver failure. Hepatology2014;59:1084. CrossRef

26. LieberCS, LeoMA, MakKM, et al.Model of nonalcoholic steatohepatitis. Am J Clin Nutr2004;79:502.

27. HuntCM, WesterkamWR, StaveGM, et al.Hepatic cytochrome P‐4503A (CYP3A) activity in the elderly. Mech Ageing Dev1992;64:189. CrossRef

28. IkemotoS, ImaokaS, HayaharaN, et al.Expression of hepatic microsomal cytochrome P450s as altered by uremia. Biochem Pharmacol1992;43:2407. CrossRef

29. Van VlierbergheH, Van DurmeF, VerdievelH, et al.Influence of low‐dose oral contraceptives, alcohol, and grapefruit on [13C] aminopyrine breath test. Dig Dis Sci2001;46:133. CrossRef

30. TakahashiM, OnozawaS, OgawaR, et al.Predictive performance of three practical approaches for grapefruit juice‐induced 2‐fold or greater increases in AUC of concomitantly administered drugs. J Clin Pharm Ther2015;40:91. CrossRef

31. WilkinsonGR. The effects of diet, aging and disease‐states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev1997;27:129. CrossRef

32. UetrechtJ. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel2001;4:55.

33. ChenM, BorlakJ, TongW. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury. Hepatology2013;58:388. CrossRef

34. TraunerM, MeierPJ, BoyerJL. Molecular pathogenesis of cholestasis. N Engl J Med1998;339:1217. CrossRef

35. BossardR, StiegerB, O'NeillB, et al.Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest1993;91:2714. CrossRef

36. StiegerB, FattingerK, MadonJ, et al.Drug‐ and estrogen‐induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology2000;118:422. CrossRef

37. FromentyB, BersonA, PessayreD. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol1997;26(Suppl 1):13. CrossRef

38. LattaM, KunstleG, LeistM, et al.Metabolic depletion of ATP by fructose inversely controls CD‐95‐ and tumor necrosis factor receptor 1‐mediated hepatic apoptosis. J Exp Med2000;191:1975. CrossRef

39. HentzeH, GantnerF, KolbSA, et al.Depletion of hepatic glutathione prevents death receptor‐dependent apoptotic and necrotic liver injury in mice. Am J Pathol2000;156:2045. CrossRef

40. JonesBE, CzajaMJIII. Intracellular signaling in response to toxic liver injury. Am J Physiol1998;275:G874.

41. McCarthyJJ, HilfikerR. The use of single‐nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol2000;18:505. CrossRef

42. JollowDJ, MitchellJR, PotterWZ, et al.Acetaminophen‐induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther1973;187:195.

43. RuprahM, MantTG, FlanaganRJ. Acute carbon tetrachloride poisoning in 19 patients: implications for diagnosis and treatment. Lancet1985;1:1027. CrossRef

44. SalfelderK, DoehnertHR, DoehnertG, et al.Fatal phosphorus poisoning: a study of forty‐five autopsy cases. Beitr Pathol1972;147:321. CrossRef

45. MakinAJ, WendonJ, WilliamsR. A 7‐year experience of severe acetaminophen‐induced hepatotoxicity (1987–1993). Gastroenterology1995;109:1907. CrossRef

46. MakinAJ, WilliamsR. Acetaminophen‐induced acute liver failure. In: LeeWM, WilliamsR(eds). Acute Liver Failure. Cambridge: Cambridge University Press, 1997: 32.

47. MitchellJR, JollowDJ, PotterWZ, et al.Acetaminophen‐induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther1973;187:185.

48. PotterWZ, DavisDC, MitchellJR, et al.Acetaminophen‐induced hepatic necrosis. 3. Cytochrome P‐450‐mediated binding in vitro. J Pharmacol Exp Ther1973;187:203.

49. HinsonJA, MichaelSL, AultSG, et al.Western blot analysis for nitrotyrosine protein adducts in livers of saline‐treated and acetaminophen‐treated mice. Toxicol Sci2000;53:467. CrossRef

50. MitchellJR, JollowDJ, PotterWZ, et al.Acetaminophen‐induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther1973;187:211.

51. ZimmermanHJ, MaddreyWC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology1995;22:767. CrossRef

52. WhitcombDC, BlockGD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA1994;272:1845. CrossRef

53. RubinE, LieberCS. Hepatic microsomal enzymes in man and rat: induction and inhibition by ethanol. Science1968;162:690. CrossRef

54. TredgerJM, SmithHM, ReadRB, et al.Effects of ethanol ingestion on the hepatotoxicity and metabolism of paracetamol in mice. Toxicology1985;36:341. CrossRef

55. BrayGP, MowatC, MuirDF, et al.The effect of chronic alcohol intake on prognosis and outcome in paracetamol overdose. Hum Exp Toxicol1991;10:435. CrossRef

56. SchiødtFV, LeeWM. Management of acetaminophen toxicity. In: KrawittEL(ed). Medical Management of Liver Disease. New York: Marcel Dekker, 1999: 325.

57. NelsonSD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis1990;10:267. CrossRef

58. RaySD, JenaN. A hepatotoxic dose of acetaminophen modulates expression of BCL‐2, BCL‐X(L), and BCL‐X(S) during apoptotic and necrotic death of mouse liver cells in vivo. Arch Toxicol2000;73:594. CrossRef

59. NguyenKA, CarboneJM, SilvaVM, et al.The PPAR activator docosahexaenoic acid prevents acetaminophen hepatotoxicity in male CD‐1 mice. J Toxicol Environ Health A1999;58:171. CrossRef

60. SchiødtFV, RochlingFA, CaseyDL, et al.Acetaminophen toxicity in an urban county hospital. N Engl J Med1997;337:1112. CrossRef

61. LarsonAM, FontanaRJ, DavernTJ, et al.; and the ALFSG. Acetaminophen‐induced acute liver failure: results of a United States multicenter, prospective study. Hepatology2005;42:1364. CrossRef

62. AcharyaSK, DasarathyS, KumerTL, et al.Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology1996;23:1448. CrossRef

63. GaribaldiRA, DrusinRE, FerebeeSH, et al.Isoniazid‐associated hepatitis. Report of an outbreak. Am Rev Respir Dis1972;106:357. CrossRef

64. NolanCM, GoldbergSV, BuskinSE. Hepatotoxicity associated with isoniazid preventive therapy: a 7‐year survey from a public health tuberculosis clinic. JAMA1999;281:1014. CrossRef

65. RamakrishnaB, ViswanathN. Diclofenac‐induced hepatitis: case report and literature review. Liver1994;14:83. CrossRef

66. O'BeirneJP, CairnsSR. Drug points: cholestatic hepatitis in association with celecoxib. BMJ2001;323:23. CrossRef

67. Carrillo‐JimenezR, NurnbergerM. Celecoxib‐induced acute pancreatitis and hepatitis: a case report. Arch Intern Med2000;160:553. CrossRef

68. KaplowitzN. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov2005;4:489. CrossRef

69. WatkinsPB, KaplowitzN, SlatteryJT, et al.Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA2006;296:87. CrossRef

70. BenichouC. Criteria of drug‐induced liver disorders. Report of an international consensus meeting. J Hepatol1990;11:272. CrossRef

71. LarreyD. Drug‐induced liver diseases. J Hepatol2000;32(1–Suppl):77. CrossRef

72. LeeWM, SchiødtFV. Fulminant hepatic failure. In: SchiffER, SorrellMF, MaddreyWC(eds). Schiff's Diseases of the Liver. Philadelphia: Lippincott‐Raven Publishers, 1999: 879.

73. SeeffLB, CuccheriniBA, ZimmermanHJ, et al.Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med1986;104:399. CrossRef

74. WangK, HuangYS, DengJF, et al.Characteristics and risk factors of acetaminophen‐induced hepatitis in Taiwan. Chung Hua I Hsueh Tsa Chih (Taipei)1999;62:369.

75. HynsonJL, SouthM. Childhood hepatotoxicity with paracetamol doses less than 150 mg/kg per day. Med J Aust1999;171:497.

76. LeeWM. Sounding board: acetaminophen hepatotoxicity and the U.S. Acute Liver Failure Study: lowering the risks of hepatic failure. Hepatology2004;40:6.

77. DavernTJII, JamesLP, HinsonJA, et al.and the ALFSG. Measurement of serum acetaminophen–protein adducts in patients with acute liver failure. Gastroenterology2006;130:687. CrossRef

78. KhandelwalN, JamesLP, SandersC, et al.Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology2011;53:567. CrossRef

79. JamesLP, LetzigL, SimpsonPM, et al.Pharmacokinetics of acetaminophen protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos2009;37:1. CrossRef

80. TraunerM, MeierPJ, BoyerJ. Molecular pathogenesis of cholestasis. N Engl J Med1998;339:1217. CrossRef

81. ChitturiS, FarrellGC. Drug‐induced cholestasis. Semin Gastrointest Dis2001;12:113.

82. LaSI, SecchiP, GrampaG, et al.Acute cholangitis induced by carbamazepine. Epilepsia1994;35:1029. CrossRef

83. BaciewiczAM, HapkeRJ, ToddCY. Cholestasis: hepatocellular reaction to trimethoprim/sulfamethoxazole. Ann Pharmacother1994;28:1310.

84. CrantockL, PrenticeR, PowellL. Cholestatic jaundice associated with captopril therapy. J Gastroenterol Hepatol1991;6:528. CrossRef

85. IqbalM, GoenkaP, YoungMF, et al.Ticlopidine‐induced cholestatic hepatitis: report of three cases and review of the literature. Dig Dis Sci1998;43:2223. CrossRef

86. DesmetVJ. Vanishing bile duct syndrome in drug‐induced liver disease. J Hepatol1997;26(Suppl 1):31. CrossRef

87. DegottC, FeldmannG, LarreyD, et al.Drug‐induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology1992;15:244. CrossRef

88. MoradpourD, AltorferJ, FluryR, et al.Chlorpromazine‐induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology1994;20:1437. CrossRef

89. OrmanES, ConjeevaramHS, VuppalanchiR, et al.Clinical and histopathologic features of fluoroquinolone‐induced liver injury. Clin Gastroenterol Hepatol2011;9:517. CrossRef

90. AlazmiWM, McHenryL, WatkinsJL, et al.Chemotherapy‐induced sclerosing cholangitis: long‐term response to endoscopic therapy. J Clin Gastroenterol2006;40:353. CrossRef

91. CarneyFM, Van DykeRA. Halothane hepatitis: a critical review. Anesth Analg1972;51:135.

92. BjörnssonE, OlssonR. Suspected drug‐induced liver fatalities reported to the WHO database. Dig Liver Dis2006;38:33. CrossRef

93. Crespo PérezL, Moreira VicenteV, Cano RuizA, et al.Anticonvulsant hypersensitivity syndrome: an entity to be remembered. Gastroenterol Hepatol2009;32:687. CrossRef

94. KnowlesSR, ShapiroLE, ShearNH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf1999;21:489. CrossRef

95. RzanyB, CorreiaO, KellyJP, et al.Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case–control study. Study Group of the international case control study on severe cutaneous adverse reactions. Lancet1999;353:2190. CrossRef

96. TaraziEM, HarterJG, ZimmermanHJ, et al.Sulindac‐associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology1993;104:569.

97. ZimmermanHJ, MaddreyWC. Toxic and drug‐induced hepatitis. In: SchiffL, SchiffER(eds). Diseases of the Liver. Philadelphia: JB Lippincott, 1993: 707.

98. IbdahJA, BennettMJ, RinaldoP, et al.A fetal fatty‐acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med1999;340:1723. CrossRef

99. BelayED, BreseeJS, HolmanRC, et al.Reye's syndrome in the United States from 1981 through 1997. N Engl J Med1999;340:1377. CrossRef

100. JeavonsPM. Non‐dose‐related side effects of valproate. Epilepsia1984;25(Suppl 1):S50. CrossRef

101. FreneauxE, LabbeG, LetteronP, et al.Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology1988;8:1056. CrossRef

102. McKenzieR, FriedMW, SallieR, et al.Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med1995;333:1099. CrossRef

103. WaldmanRJ, HallWN, McGeeH, et al.Aspirin as a risk factor in Reye's syndrome. JAMA1982;247:3089. CrossRef

104. GlasgowJF, MooreR. Reye's syndrome 30 years on. BMJ1993;307:950. CrossRef

105. ChalasaniN, AljadheyH, KestersonJ, et al.Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology2004;126:1287. CrossRef

106. SladeJH, AlattarML, FogelmanDR, et al.Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer2009;8:225. CrossRef

107. BissonnetteJ, GénéreuxA, CôtéJ, et al.Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. J Gastroenterol Hepatol2012;27:1336. CrossRef

108. LawalTO, FarrisAB, El‐RayesBF, et al.Oxaliplatin‐induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. Clin Colorectal Cancer2012;11:224. CrossRef

109. NavarroVJ, LucenaMI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis2014;34:172. CrossRef

110. LeeWM, StravitzRT, LarsonAM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure. Hepatology2012;55:965. CrossRef

111. StravitzRT, KramerAH, DavernT, et al.Intensive care of patients with acute liver failure: Recommendations of the Acute Liver Failure Study Group. Crit Care Med2007;35:2498. CrossRef

112. LeeWM, HynanLS, RossaroL, et al.N‐acetylcysteine improves transplant‐free survival in early stage non‐acetaminophen acute liver failure. Gastroenterology2009;137:856. CrossRef

113. AithalGP, RawlinsMD, DayCP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol2000;33:949. CrossRef

114. DananG, BenichouC. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug‐induced liver injuries. J Clin Epidemiol1993;46:1323. CrossRef

115. LucenaMI, CamargoR, AndradeRJ, et al.Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology2001;33:123. CrossRef

116. FontanaRJ, WatkinsPB, BonkovskyHL, et al.Drug‐Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf2009;32:55. CrossRef

117. RockeyDC, SeeffLB, RochonJ, et al.Causality assessment in drug‐induced liver injury using a structured expert opinion process: comparison to the Roussel‐Uclaf causality assessment method. Hepatology2010;51:2117. CrossRef

118. AithalPG, DayCP. The natural history of histologically proved drug induced liver disease. Gut1999;44:731. CrossRef

119. TolmanKG. Hepatotoxicity of antirheumatic drugs. J Rheumatol Suppl1990;22:6.

120. MosesPL, SchroederB, AlkhatibO, et al.Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol1999;94:1393. CrossRef

121. FontanaRJ, McCashlandTM, BennerKG, et al.Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg1999;5:480. CrossRef

122. GitlinN, JulieNL, SpurrCL, et al.Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med1998;129:36. CrossRef

123. Neuschwander‐TetriBA, IsleyWL, OkiJC, et al.Troglitazone‐induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med1998;129:38. CrossRef

124. MurphyEJ, DavernTJ, ShakilAO, et al.Troglitazone‐induced fulminant hepatic failure. Dig Dis Sci2000;45:549. CrossRef

125. MalikAH, PrasadP, SaboorianMH, et al.Hepatic injury due to troglitazone. Dig Dis Sci2000;45:210. CrossRef

126. JagannathS, RaiR. Rapid‐onset subfulminant liver failure associated with troglitazone. Ann Intern Med2000;132:677. CrossRef

127. LeeWM, LarreyD, OlssonR, et al.Hepatic findings in long‐term clinical trials of ximelagatran. Drug Saf2005;28:351. CrossRef

128. ClayKD, HansonJS, PopeSD, et al.Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med2006;144:215.

129. Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4266m1.pdf. Results of the FDA Anti‐infective Advisory Committee meeting, December 14–15, 2006.

130. CarneX, ArnaizJA. Methodological and political issues in clinical pharmacology research by the year 2000. Eur J Clin Pharmacol2000;55:781. CrossRef

131. HoofnagleJH, SerranoJ, KnobenJE, et al.LiverTox: a website on drug‐induced liver injury. Hepatology2013;57:873. CrossRef

132. AdedoyinA, ArnsPA, RichardsWO, et al.Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther1998;64:8. CrossRef

133. WeltmanMD, FarrellGC, HallP, et al.Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology1998;27:128. CrossRef

134. FroomesPR, MorganDJ, SmallwoodRA, et al.Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology1999;116:915. CrossRef

135. SchenkerS, MartinRR, HoyumpaAM. Antecedent liver disease and drug toxicity. J Hepatol1999;31:1098. CrossRef

136. GrahamDJ, DrinkardCR, ShatinD, et al.Liver enzyme monitoring in patients treated with troglitazone. JAMA2001;286:831. CrossRef

137. NakadA, BatailleL, HamoirV, et al.Atorvastatin‐induced acute hepatitis with absence of cross‐toxicity with simvastatin. Lancet1999;353:1763. CrossRef

138. LeonardC, BurkeCM, O'KeaneC, et al.“Golf ball liver”: agent orange hepatitis. Gut1997;40:687. CrossRef

139. BaylorP, WilliamsK. Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. Clin Infect Dis1999;29:1350. CrossRef

140. EhrenforthS, SchenkJF, ScharrerI. Liver damage induced by coumarin anticoagulants. Semin Thromb Hemost1999;25:79. CrossRef

141. FriedmanG, LamoureuxE, SherkerAH. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci1999;44:1362. CrossRef

142. Romero‐GomezM, MirallesEJ, DiazEG, et al.Hepatotoxicity induced by fosinopril. J Hepatol2001;35:309. CrossRef

143. JacobsonMA, HanksDK, FerrellLD. Fatal acute hepatic necrosis due to fluconazole. Am J Med1994;96:188. CrossRef

144. CaiQ, BensonMA, TalbotTJ, et al.Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc1999;74:692. CrossRef

145. VergisE, PatersonDL, SinghN. Indinavir‐associated hepatitis in patients with advanced HIV infection. Int J STD AIDS1998;9:53. CrossRef

146. SpahrL, Rubbia‐BrandtL, MarinescuO, et al.Acute fatal hepatitis related to levofloxacin. J Hepatol2001;35:308. CrossRef

147. BoschX. Losartan‐induced hepatotoxicity. JAMA1997;278:1572. CrossRef

148. DeltenreP, BersonA, MarcellinP, et al.Mesalazine (5‐aminosalicylic acid) induced chronic hepatitis. Gut1999;44:886. CrossRef

149. BabichMM, PikeI, ShiffmanML. Metformin‐induced acute hepatitis. Am J Med1998;104:490. CrossRef

150. Aranda‐MichelJ, KoehlerA, BejaranoPA, et al.Nefazodone‐induced liver failure: report of three cases. Ann Intern Med1999;130:285. CrossRef

151. Lopez‐NavidadA, DomingoP, CadafalchJ, et al.Norfloxacin‐induced hepatotoxicity. J Hepatol1990;11:277. CrossRef

152. Romero‐GomezM, SuarezGE, FernandezMC. Norfloxacin‐induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis. Am J Gastroenterol1999;94:2324.

153. BenbowSJ, GillG. Paroxetine and hepatotoxicity. BMJ1997;314:1387. CrossRef

154. RoshJR, DellertSF, NarkewiczM, et al.Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics1998;101:921. CrossRef

155. HartlebM, RymarczykG, JanuszewskiK. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol1999;94:1388. CrossRef

156. RibeiroJM, LucasM, BaptistaA, et al.Fatal hepatitis associated with ranitidine. Am J Gastroenterol2000;95:559.

157. KrebsS, DormannH, Muth‐SelbachU, et al.Risperidone‐induced cholestatic hepatitis. Eur J Gastroenterol Hepatol2001;13:67. CrossRef

158. BenazziF. Risperidone‐induced hepatotoxicity. Pharmacopsychiatry1998;31:241. CrossRef

159. GuptaAK, del RossoJQ, LyndeCW, et al.Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol1998;23:64. CrossRef

160. SpahrL, Rubbia‐BrandtL, BurkhardPR, et al.Tolcapone‐related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig Dis Sci2000;45:1881. CrossRef

161. ColosimoC. The rise and fall of tolcapone. J Neurol1999;246:880. CrossRef

162. FernandesNF, MartinRR, SchenkerS. Trazodone‐induced hepatotoxicity: a case report with comments on drug‐induced hepatotoxicity. Am J Gastroenterol2000;95:532.

163. LazarczykDA, GoldsteinNS, GordonSC. Trovafloxacin hepatotoxicity. Dig Dis Sci2001;46:925. CrossRef

164. ChenHJ, BlochKJ, MacleanJA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med2000;342:359. CrossRef

165. McLaughlinDB, EadieMJ, Parker‐ScottSL, et al.Valproate metabolism during valproate‐associated hepatotoxicity in a surviving adult patient. Epilepsy Res2000;41:259. CrossRef

166. KonigSA, SchenkM, SickC, et al.Fatal liver failure associated with valproate therapy in a patient with Friedrich's disease: review of valproate hepatotoxicity in adults. Epilepsia1999;407:1036. CrossRef

167. CardonaX, AvilaA, CastellanosP. Venlafaxine‐associated hepatitis. Ann Intern Med2000;132:417. CrossRef

168. SongJ, DeresinskiS. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs2005;6:170.